LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Alternative complexes formed by the Escherichia coli clamp loader accessory protein HolC (x) with replication protein HolD (ψ) and repair protein YoaA.

    Sutera, Vincent A / Weeks, Savannah J / Dudenhausen, Elizabeth E / Baggett, Helen B Rappe / Shaw, McKay C / Brand, Kirsten A / Glass, David J / Bloom, Linda B / Lovett, Susan T

    DNA repair

    2021  Volume 100, Page(s) 103006

    Abstract: Efficient and faithful replication of DNA is essential for all organisms. However, the replication fork frequently encounters barriers that need to be overcome to ensure cell survival and genetic stability. Cells must carefully balance and regulate ... ...

    Abstract Efficient and faithful replication of DNA is essential for all organisms. However, the replication fork frequently encounters barriers that need to be overcome to ensure cell survival and genetic stability. Cells must carefully balance and regulate replication vs. repair reactions. In Escherichia coli, the replisome consists of the DNA polymerase III holoenzyme, including DNA polymerase, proofreading exonuclease, processivity clamp and clamp loader, as well as a fork helicase, DnaB and primase, DnaG. We provide evidence here that one component of the clamp loader complex, HolC (or χ) plays a dual role via its ability to form 2 mutually exclusive complexes: one with HolD (or ψ) that recruits the clamp-loader and hence the DNA polymerase holoenzyme and another with helicase-like YoaA protein, a DNA-damage inducible repair protein. By yeast 2 hybrid analysis, we show that two residues of HolC, F64 and W57, at the interface in the structure with HolD, are required for interaction with HolD and for interaction with YoaA. Mutation of these residues does not interfere with HolC's interaction with single-strand DNA binding protein, SSB. In vivo, these mutations fail to complement the poor growth and sensitivity to azidothymidine, a chain-terminating replication inhibitor. In support of the notion that these are exclusive complexes, co-expression of HolC, HolD and YoaA, followed by pulldown of YoaA, yields a complex with HolC but not HolD. YoaA fails to pulldown HolC-F64A. We hypothesize that HolC, by binding with SSB, can recruit the DNA polymerase III holoenzyme through HolD, or an alternative repair complex with YoaA helicase.
    MeSH term(s) DNA Polymerase III/metabolism ; DNA Repair ; DNA Replication ; DNA, Bacterial/metabolism ; Escherichia coli/genetics ; Escherichia coli/metabolism ; Escherichia coli Proteins/metabolism ; Protein Binding ; Protein Conformation
    Chemical Substances DNA, Bacterial ; Escherichia coli Proteins ; holD protein, E coli ; DNA Polymerase III (EC 2.7.7.7) ; holC protein, E coli (EC 2.7.7.7)
    Language English
    Publishing date 2021-02-02
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2071608-4
    ISSN 1568-7856 ; 1568-7864
    ISSN (online) 1568-7856
    ISSN 1568-7864
    DOI 10.1016/j.dnarep.2020.103006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models.

    Degagné, Émilie / Donohoue, Paul D / Roy, Suparna / Scherer, Jessica / Fowler, Tristan W / Davis, Ryan T / Reyes, Gustavo A / Kwong, George / Stanaway, Morena / Larroca Vicena, Vanina / Mutha, Devin / Guo, Raymond / Edwards, Leslie / Schilling, Benjamin / Shaw, McKay / Smith, Stephen C / Kohrs, Bryan / Kufeldt, Heinrich J / Churchward, Glen /
    Ruan, Finey / Nyer, David B / McSweeney, Kyle / Irby, Matthew J / Fuller, Christopher K / Banh, Lynda / Toh, Mckenzi S / Thompson, Matthew / Owen, Arthur L G / An, Zili / Gradia, Scott / Skoble, Justin / Bryan, Mara / Garner, Elizabeth / Kanner, Steven B

    Cancer immunology research

    2024  Volume 12, Issue 4, Page(s) 462–477

    Abstract: Allogeneic chimeric antigen receptor (CAR) T cell therapies hold the potential to overcome many of the challenges associated with patient-derived (autologous) CAR T cells. Key considerations in the development of allogeneic CAR T cell therapies include ... ...

    Abstract Allogeneic chimeric antigen receptor (CAR) T cell therapies hold the potential to overcome many of the challenges associated with patient-derived (autologous) CAR T cells. Key considerations in the development of allogeneic CAR T cell therapies include prevention of graft-vs-host disease (GvHD) and suppression of allograft rejection. Here, we describe preclinical data supporting the ongoing first-in-human clinical study, the CaMMouflage trial (NCT05722418), evaluating CB-011 in patients with relapsed/refractory multiple myeloma. CB-011 is a hypoimmunogenic, allogeneic anti-B-cell maturation antigen (BCMA) CAR T cell therapy candidate. CB-011 cells feature 4 genomic alterations and were engineered from healthy donor-derived T cells using a Cas12a CRISPR hybrid RNA-DNA (chRDNA) genome-editing technology platform. To address allograft rejection, CAR T cells were engineered to prevent endogenous HLA class I complex expression and overexpress a single-chain polyprotein complex composed of beta-2 microglobulin (B2M) tethered to HLA-E. In addition, T-cell receptor (TCR) expression was disrupted at the TCR alpha constant locus in combination with the site-specific insertion of a humanized BCMA-specific CAR. CB-011 cells exhibited robust plasmablast cytotoxicity in vitro in a mixed lymphocyte reaction in cell cocultures derived from patients with multiple myeloma. In addition, CB-011 cells demonstrated suppressed recognition by and cytotoxicity from HLA-mismatched T cells. CB-011 cells were protected from natural killer cell-mediated cytotoxicity in vitro and in vivo due to endogenous promoter-driven expression of B2M-HLA-E. Potent antitumor efficacy, when combined with an immune-cloaking armoring strategy to dampen allograft rejection, offers optimized therapeutic potential in multiple myeloma. See related Spotlight by Caimi and Melenhorst, p. 385.
    MeSH term(s) Humans ; Multiple Myeloma/genetics ; Multiple Myeloma/therapy ; B-Cell Maturation Antigen/metabolism ; HLA-E Antigens ; T-Lymphocytes ; Receptors, Antigen, T-Cell ; Immunotherapy, Adoptive ; Histocompatibility Antigens Class I/metabolism ; Hematopoietic Stem Cell Transplantation ; Allografts/pathology
    Chemical Substances B-Cell Maturation Antigen ; HLA-E Antigens ; Receptors, Antigen, T-Cell ; Histocompatibility Antigens Class I
    Language English
    Publishing date 2024-02-12
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2732489-8
    ISSN 2326-6074 ; 2326-6066
    ISSN (online) 2326-6074
    ISSN 2326-6066
    DOI 10.1158/2326-6066.CIR-23-0679
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top